NAC : A well-known mucolytic agent it breaks down thick mucus, improving breathing in conditions like asthma, COPD, and chronic bronchitis
Saxenda (liraglutide) Approved uses: Children ages 12-17 with obesity and adults with overweight, obesity, or a weight-related condition Drug type: Once-daily injection Doses: 0.6 mg (starting dose), 1.2 mg, 1.8 mg, 2.4 mg, and 3 mg
Anti-Inflammatory Properties: May assist in reducing inflammation and aiding the body's natural recovery process
Histopathological analysis supported the clinical and planimetric data
In this scenario, a 22% reduction in the extraction ratio has resulted in a 200% (three-fold) increase in the amount of drug reaching the systemic circulation